Weekly Digest – October 2026 Weekly Digest – October 2026 08 October 2026: Enhertu approved in China for HER2-positive early Breast cancer with residual disease Daiichi Sankyo and AstraZeneca announced that Enhertu has been approved in China as adjuvant treatment […]
Weekly Digest – October 2026 Weekly Digest – October 2026 08 October 2026: Datroway approved in China for metastatic TNBC ineligible for PD-1/PD-L1 inhibitors Daiichi Sankyo and AstraZeneca announced that Datroway has been approved in China for adults with unresectable […]
Weekly Digest – October 2026 Weekly Digest – October 2026 07 October 2026: AbbVie’s Temab-A receives FDA Breakthrough Therapy Designations for CRC and NSCLC AbbVie announced that the U.S. FDA has granted two Breakthrough Therapy Designations to Telisotuzumab adizutecan, its […]
Weekly Digest – October 2026 Weekly Digest – October 2026 08 October 2026: [²¹²Pb]PSV359 receives FDA Fast Track Designation for FAP-positive solitary fibrous tumors Perspective Therapeutics has received U.S. FDA Fast Track Designation for [²¹²Pb]PSV359 for adults with locally advanced […]
Weekly Digest – October 2026 Weekly Digest – October 2026 05 October 2026: Crescent Biopharma receives FDA IND clearance for CR-002 in Solid tumors Crescent Biopharma announced that the U.S. FDA has cleared the Investigational New Drug application for CR-002, […]
Weekly Digest – October 2026 Weekly Digest – October 2026 02 October 2026: AstraZeneca and Daiichi Sankyo collaborate with Summit Therapeutics to evaluate Datroway plus Ivonescimab across multiple tumor types AstraZeneca and Daiichi Sankyo have entered a clinical collaboration with Summit […]
